Pharmaceutical Companies Accelerate Innovation as AI-Driven Drug Discovery Gains Momentum

　　【Pharmaceutical Network Industry News】Historically, new drug development has been characterized by high design complexity, substantial costs, and lengthy timelines. Industry averages previously indicated that successfully bringing a new drug to market required "10 years and $1 billion." Against this backdrop, as the new drug R&D sector has grown increasingly active and development costs continue to climb in recent years, pharmaceutical companies, seeking to alleviate investment pressures, have increasingly leveraged AI platforms for drug discovery and development, with such cases steadily on the rise.
 

Recently, reports indicated that Zhejiang Jingxin Pharmaceutical Co.,Ltd. and AI drug discovery company XtalPi have entered into a project collaboration to jointly advance the R&D of small-molecule antidepressant drugs. It is reported that this collaboration, focusing on the development of an innovative small-molecule antidepressant with independent intellectual property rights, will see both parties apply AI technology to the design, optimization, and validation of preclinical candidate drugs for the project, thereby accelerating the development of urgently needed therapies for patients with depression.
 

Specifically, the collaboration between Zhejiang Jingxin Pharmaceutical Co., Ltd. and XtalPi will leverage XtalPi's leading integrated artificial intelligence drug discovery platform to focus on the three-dimensional structural features of depression-related targets. By utilizing AI molecular generation and structure-based drug design to generate a targeted molecular library with structural diversity, and employing high-precision binding energy evaluation methods alongside multiple ADMET prediction models for molecular screening, the partnership aims to obtain novel-scaffold candidate molecules with outstanding properties in activity, selectivity, druggability, and safety. This initiative seeks to address common issues associated with existing antidepressant treatment regimens, such as treatment inefficacy, high relapse rates, slow onset of action, and side effects.
 

Additionally, prior to this, Simcere Pharmaceutical and AlphaMab Biologicals jointly announced that they have signed an exclusive license agreement for the novel anti-tumor drug ALM005. According to available information, AlphaMab Biologicals is a technology-driven enterprise that accelerates new drug development by leveraging artificial intelligence for drug screening and optimization. Focusing on a data-driven approach, the company utilizes machine learning models for lead compound design and discovery, as well as optimizing the multi-target selectivity and druggability profiles of drug candidates. The ALM005 compound involved in this collaboration is a highly valuable molecule discovered based on AlphaMab Biologicals' AI technology.
 

In addition to the aforementioned pharmaceutical companies, leveraging AI to accelerate innovation has become a widespread practice within the industry. Notably, alongside pharmaceutical firms continuously accelerating their strategic expansion in the AI drug discovery sector, capital markets in China have also demonstrated intense interest in AI-driven drug development. According to incomplete statistics, as of now, financing and investment events in the AI pharmaceutical sector in China have exceeded 15.
 

Recently, Camdissen (Beijing) announced the completion of a Pre-Series A financing round of tens of millions of RMB. The funds raised in this round will be primarily allocated to the development of an innovative small-molecule drug platform based on three-dimensional protein structures, as well as computation-driven new drug R&D and related fields. Meanwhile, XtalPi also announced the completion of a new Series D financing round of $400 million, achieving a post-money valuation of over RMB 13 billion.
 

Industry experts believe that, overall, the AI-driven drug discovery and development sector has begun to enter a period of heightened activity. Looking ahead, driven by broader industry trends, AI pharmaceutical R&D is expected to achieve further breakthroughs, and the innovative achievements of domestic pharmaceutical companies are also likely to materialize at an accelerating pace.